LYCOS INC
424B3, 1999-11-10
COMPUTER PROGRAMMING, DATA PROCESSING, ETC.
Previous: LYCOS INC, 424B3, 1999-11-10
Next: JMI EQUITY FUND LP, 4, 1999-11-10



<PAGE>

                                        FILED PURSUANT TO RULE 424(b)(3) AND (c)
                                                           FILE NUMBER 333-61413

               TWENTY-SEVENTH PROSPECTUS SUPPLEMENT TO PROSPECTUS
                              DATED AUGUST 24, 1998

                                8,370,248 SHARES

                                   LYCOS, INC.

                                  COMMON STOCK

This Twenty-Seventh Prospectus Supplement (the "Twenty-Seventh Prospectus
Supplement") supplements the Prospectus dated August 24, 1998 (the
"Prospectus"), the Prospectus Supplement dated September 15, 1998 (the "First
Prospectus Supplement"), the Second Prospectus Supplement dated October 28,
1998 (the "Second Prospectus Supplement"), the Third Prospectus Supplement
dated November 12, 1998 (the "Third Prospectus Supplement"), the Fourth
Prospectus Supplement dated November 18, 1998 (the "Fourth Prospectus
Supplement"), the Fifth Prospectus Supplement dated November 19, 1998 (the
"Fifth Prospectus Supplement"), the Sixth Prospectus Supplement dated
December 1, 1998 (the "Sixth Prospectus Supplement"), the Seventh Prospectus
Supplement dated December 2, 1998 (the "Seventh Prospectus Supplement"), the
Eighth Prospectus Supplement dated December 4, 1998 (the "Eighth Prospectus
Supplement"), the Ninth Prospectus Supplement dated December 21, 1998 (the
"Ninth Prospectus Supplement"), the Tenth Prospectus Supplement dated
December 28, 1998 (the "Tenth Prospectus Supplement"), the Eleventh
Prospectus Supplement dated January 14, 1999 (the "Eleventh Prospectus
Supplement"), the Twelfth Prospectus Supplement dated February 12, 1999 (the
"Twelfth Prospectus Supplement"), the Thirteenth Prospectus Supplement dated
March 2, 1999 (the "Thirteenth Prospectus Supplement"), the Fourteenth
Prospectus Supplement dated March 25, 1999 (the "Fourteenth Prospectus
Supplement"), the Fifteenth Prospectus Supplement dated April 27, 1999 (the
"Fifteenth Prospectus Supplement"), the Sixteenth Prospectus Supplement dated
June 16, 1999 (the "Sixteenth Prospectus Supplement"), the Seventeenth
Prospectus Supplement dated July 6, 1999 (the "Seventeenth Prospectus
Supplement"), the Eighteenth Prospectus Supplement dated July 8, 1999 (the
"Eighteenth Prospectus Supplement"), the Nineteenth Prospectus Supplement
dated July 19, 1999 (the "Nineteenth Prospectus Supplement"), the Twentieth
Prospectus Supplement dated August 26, 1999 (the "Twentieth Prospectus
Supplement"), the Twenty-First Prospectus Supplement dated September 9, 1999
(the "Twenty-First Prospectus Supplement"), the Twenty-Second Prospectus
Supplement dated September 17, 1999 (the "Twenty-Second Prospectus
Supplement"), the Twenty-Third Prospectus Supplement dated October 6, 1999
(the "Twenty-Third Prospectus Supplement"), the Twenty-Fourth Prospectus
Supplement dated October 13, 1999 (the " Twenty-Fourth Prospectus
Supplement"), the Twenty-Fifth Prospectus Supplement, dated October 19, 1999
(the "Twenty-Fifth Prospectus Supplement") and the Twenty-Sixth Prospectus
Supplement, dated November 8, 1999 (the "Twenty-Sixth Prospectus Supplement")
of Lycos, Inc. ("Lycos" or the "Company") relating to the public offering,
which is not being underwritten, and sale of up to 8,370,248 shares of Common
Stock, par value $0.01 per share (the "Shares") of the Company,

<PAGE>

which may be offered and sold from time to time by certain stockholders of the
Company or by pledgees, donees, transferees or other successors in interest that
receive such shares as a gift, partnership distribution or other non-sale
related transfer (the "Selling Stockholders"). The Company will receive no part
of the proceeds of such sales. The Shares were originally issued or reserved for
issuance by the Company in connection with the Company's acquisition of
WhoWhere? Inc., a California corporation, by and through a merger of a
wholly-owned subsidiary of Lycos, What Acquisition Corp., with and into
WhoWhere? Inc. (the "Acquisition"). The "Selling Stockholders" Section of the
Prospectus, the First Prospectus Supplement, the Second Prospectus Supplement,
the Third Prospectus Supplement, the Fourth Prospectus Supplement, the Fifth
Prospectus Supplement, the Sixth Prospectus Supplement, the Seventh Prospectus
Supplement, the Eighth Prospectus Supplement, the Ninth Prospectus Supplement,
the Tenth Prospectus Supplement, the Eleventh Prospectus Supplement, the Twelfth
Prospectus Supplement, the Thirteenth Prospectus Supplement, the Fourteenth
Prospectus Supplement, the Fifteenth Prospectus Supplement, the Sixteenth
Prospectus Supplement, the Seventeenth Prospectus Supplement, the Eighteenth
Prospectus Supplement, the Nineteenth Prospectus Supplement, the Twentieth
Prospectus Supplement, the Twenty-First Prospectus Supplement, the Twenty-Second
Prospectus Supplement, the Twenty-Third Prospectus Supplement, the Twenty-Fourth
Prospectus Supplement, the Twenty-Fifth Prospectus Supplement and the
Twenty-Sixth Prospectus Supplement are hereby supplemented to reflect the gift
made by Dale Fuller to US Clearing FBO Young Life in the amount of 4,500 shares
after the date of the Prospectus, the First Prospectus Supplement, the Second
Prospectus Supplement, the Third Prospectus Supplement, the Fourth Prospectus
Supplement, the Fifth Prospectus Supplement, the Sixth Prospectus Supplement,
the Seventh Prospectus Supplement, the Eighth Prospectus Supplement, the Ninth
Prospectus Supplement, the Tenth Prospectus Supplement, the Eleventh Prospectus
Supplement, the Twelfth Prospectus Supplement, the Thirteenth Prospectus
Supplement, the Fourteenth Prospectus Supplement, the Fifteenth Prospectus
Supplement, the Sixteenth Prospectus Supplement, the Seventeenth Prospectus
Supplement, the Eighteenth Prospectus Supplement, the Nineteenth Prospectus
Supplement, the Twentieth Prospectus Supplement, the Twenty-First Prospectus
Supplement, the Twenty-Second Prospectus Supplement, the Twenty-Third Prospectus
Supplement, the Twenty-Fourth Prospectus Supplement, the Twenty-Fifth Prospectus
Supplement and the Twenty-Sixth Prospectus Supplement. This Twenty-Seventh
Prospectus Supplement should be read in conjunction with the Prospectus, the
First Prospectus Supplement, the Second Prospectus Supplement, the Third
Prospectus Supplement, the Fourth Prospectus Supplement, the Fifth Prospectus
Supplement, the Sixth Prospectus Supplement, the Seventh


                                       2
<PAGE>

Prospectus Supplement, the Eighth Prospectus Supplement, the Ninth Prospectus
Supplement, the Tenth Prospectus Supplement, the Eleventh Prospectus Supplement,
the Twelfth Prospectus Supplement, the Thirteenth Prospectus Supplement, the
Fourteenth Prospectus Supplement, the Fifteenth Prospectus Supplement, the
Sixteenth Prospectus Supplement, the Seventeenth Prospectus Supplement, the
Eighteenth Prospectus Supplement, the Nineteenth Prospectus Supplement, the
Twentieth Prospectus Supplement, the Twenty-First Prospectus Supplement, the
Twenty-Second Prospectus Supplement, the Twenty-Third Prospectus Supplement, the
Twenty-Fourth Prospectus Supplement, the Twenty-Fifth Prospectus Supplement and
the Twenty-Sixth Prospectus Supplement and is qualified by reference to the
Prospectus, the First Prospectus Supplement, the Second Prospectus Supplement,
the Third Prospectus Supplement, the Fourth Prospectus Supplement, the Fifth
Prospectus Supplement, the Sixth Prospectus Supplement, the Seventh Prospectus
Supplement, the Eighth Prospectus Supplement, the Ninth Prospectus Supplement,
the Tenth Prospectus Supplement, the Eleventh Prospectus Supplement, the Twelfth
Prospectus Supplement, the Thirteenth Prospectus Supplement, the Fourteenth
Prospectus Supplement, the Fifteenth Prospectus Supplement, the Sixteenth
Prospectus Supplement, the Seventeenth Prospectus Supplement, the Eighteenth
Prospectus Supplement, the Nineteenth Prospectus Supplement, the Twentieth
Prospectus Supplement, the Twenty-First Prospectus Supplement, the Twenty-Second
Prospectus Supplement, the Twenty-Third Prospectus Supplement, the Twenty-Fourth
Prospectus Supplement, the Twenty-Fifth Prospectus Supplement and the
Twenty-Sixth Prospectus Supplement except to the extent that the information
herein contained supersedes the information contained in the Prospectus, the
First Prospectus Supplement, the Second Prospectus Supplement, the Third
Prospectus Supplement, the Fourth Prospectus Supplement, the Fifth Prospectus
Supplement, the Sixth Prospectus Supplement, the Seventh Prospectus Supplement,
the Eighth Prospectus Supplement, the Ninth Prospectus Supplement, the Tenth
Prospectus Supplement, the Eleventh Prospectus Supplement, the Twelfth
Prospectus, the Thirteenth Prospectus Supplement, the Fourteenth Prospectus
Supplement, the Fifteenth Prospectus Supplement, the Sixteenth Prospectus
Supplement, the Seventeenth Prospectus Supplement, the Eighteenth Prospectus
Supplement, the Nineteenth Prospectus Supplement, the Twentieth Prospectus
Supplement, the Twenty-First Prospectus Supplement, the Twenty-Second Prospectus
Supplement, Twenty-Third Prospectus Supplement, Twenty-Fourth Prospectus
Supplement, the Twenty-Fifth Prospectus Supplement and the Twenty-Sixth
Prospectus Supplement. Capitalized terms used in this Twenty-Seventh Prospectus
Supplement and not otherwise defined herein have the meanings specified in the
Prospectus.


                                       3
<PAGE>

            THE DATE OF THIS TWENTY-SEVENTH PROSPECTUS SUPPLEMENT IS
                                NOVEMBER 10, 1999

                              SELLING STOCKHOLDERS

         On October 29, 1999, of the Shares beneficially owned by Dale Fuller
reflected in the Prospectus and the supplements thereto, 4,500 of which were
gifted to US Clearing FBO Young Life. The table of Selling Stockholders in the
Prospectus and the supplements thereto are hereby amended to reflect such gift
and supplemented to specifically include Shares received in such gift.


                                       4


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission